Selected research
Industry Research
Free Circulating Tumor Cell Detection Industry Research Report 2026
Market perspective
The global Free Circulating Tumor Cell Detection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Free Circulating Tumor Cell Detection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Free Circulating Tumor Cell Detection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Free Circulating Tumor Cell Detection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Free Circulating Tumor Cell Detection include Thermo Fisher Scientific, F. Hoffmann-La Roche AG, Qiagen, Sysmex Europe SE, Rarecyte, Fluxion Biosciences Inc., Bio-Rad Laboratories Inc., Biocept Inc. and ANGLE plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Free Circulating Tumor Cell Detection market in terms of revenue (US$ million) and, where applicable, sales volume (Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Free Circulating Tumor Cell Detection Market by Company
Thermo Fisher Scientific
F. Hoffmann-La Roche AG
Qiagen
Sysmex Europe SE
Rarecyte
Fluxion Biosciences Inc.
Bio-Rad Laboratories Inc.
Biocept Inc.
ANGLE plc
Free Circulating Tumor Cell Detection Segment by Type
RNA Detection
Protein Marker Detection
Gene Marker Detection
Free Circulating Tumor Cell Detection Segment by Application
Hospital
Physical Examination Center
Free Circulating Tumor Cell Detection Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Free Circulating Tumor Cell Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Free Circulating Tumor Cell Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Free Circulating Tumor Cell Detection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Free Circulating Tumor Cell Detection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Free Circulating Tumor Cell Detection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Free Circulating Tumor Cell Detection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- RNA Detection
- Protein Marker Detection
- Gene Marker Detection
Applications
- Hospital
- Physical Examination Center
Companies covered
- Thermo Fisher Scientific
- F. Hoffmann-La Roche AG
- Qiagen
- Sysmex Europe SE
- Rarecyte
- Fluxion Biosciences Inc.
- Bio-Rad Laboratories Inc.
- Biocept Inc.
- ANGLE plc
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Free Circulating Tumor Cell Detection Market Size (2021-2032)
- 2.2.2 Global Free Circulating Tumor Cell Detection Sales (2021-2032)
- 2.2.3 Global Free Circulating Tumor Cell Detection Market Average Price (2021-2032)
- 2.3 Free Circulating Tumor Cell Detection by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 RNA Detection
- 2.3.3 Protein Marker Detection
- 2.3.4 Gene Marker Detection
- 2.4 Free Circulating Tumor Cell Detection by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Physical Examination Center
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Free Circulating Tumor Cell Detection Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Free Circulating Tumor Cell Detection Sales (Units) of Manufacturers (2021-2026)
- 3.3 Global Free Circulating Tumor Cell Detection Revenue of Manufacturers (2021-2026)
- 3.4 Global Free Circulating Tumor Cell Detection Average Price by Manufacturers (2021-2026)
- 3.5 Global Free Circulating Tumor Cell Detection Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Free Circulating Tumor Cell Detection, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Free Circulating Tumor Cell Detection, Product Type & Application
- 3.8 Global Manufacturers of Free Circulating Tumor Cell Detection, Established Date
- 3.9 Global Free Circulating Tumor Cell Detection Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Thermo Fisher Scientific
- 4.1.1 Thermo Fisher Scientific Company Information
- 4.1.2 Thermo Fisher Scientific Business Overview
- 4.1.3 Thermo Fisher Scientific Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Thermo Fisher Scientific Free Circulating Tumor Cell Detection Product Portfolio
- 4.1.5 Thermo Fisher Scientific Recent Developments
- 4.2 F. Hoffmann-La Roche AG
- 4.2.1 F. Hoffmann-La Roche AG Company Information
- 4.2.2 F. Hoffmann-La Roche AG Business Overview
- 4.2.3 F. Hoffmann-La Roche AG Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 F. Hoffmann-La Roche AG Free Circulating Tumor Cell Detection Product Portfolio
- 4.2.5 F. Hoffmann-La Roche AG Recent Developments
- 4.3 Qiagen
- 4.3.1 Qiagen Company Information
- 4.3.2 Qiagen Business Overview
- 4.3.3 Qiagen Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Qiagen Free Circulating Tumor Cell Detection Product Portfolio
- 4.3.5 Qiagen Recent Developments
- 4.4 Sysmex Europe SE
- 4.4.1 Sysmex Europe SE Company Information
- 4.4.2 Sysmex Europe SE Business Overview
- 4.4.3 Sysmex Europe SE Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Sysmex Europe SE Free Circulating Tumor Cell Detection Product Portfolio
- 4.4.5 Sysmex Europe SE Recent Developments
- 4.5 Rarecyte
- 4.5.1 Rarecyte Company Information
- 4.5.2 Rarecyte Business Overview
- 4.5.3 Rarecyte Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Rarecyte Free Circulating Tumor Cell Detection Product Portfolio
- 4.5.5 Rarecyte Recent Developments
- 4.6 Fluxion Biosciences Inc.
- 4.6.1 Fluxion Biosciences Inc. Company Information
- 4.6.2 Fluxion Biosciences Inc. Business Overview
- 4.6.3 Fluxion Biosciences Inc. Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Fluxion Biosciences Inc. Free Circulating Tumor Cell Detection Product Portfolio
- 4.6.5 Fluxion Biosciences Inc. Recent Developments
- 4.7 Bio-Rad Laboratories Inc.
- 4.7.1 Bio-Rad Laboratories Inc. Company Information
- 4.7.2 Bio-Rad Laboratories Inc. Business Overview
- 4.7.3 Bio-Rad Laboratories Inc. Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Bio-Rad Laboratories Inc. Free Circulating Tumor Cell Detection Product Portfolio
- 4.7.5 Bio-Rad Laboratories Inc. Recent Developments
- 4.8 Biocept Inc.
- 4.8.1 Biocept Inc. Company Information
- 4.8.2 Biocept Inc. Business Overview
- 4.8.3 Biocept Inc. Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biocept Inc. Free Circulating Tumor Cell Detection Product Portfolio
- 4.8.5 Biocept Inc. Recent Developments
- 4.9 ANGLE plc
- 4.9.1 ANGLE plc Company Information
- 4.9.2 ANGLE plc Business Overview
- 4.9.3 ANGLE plc Free Circulating Tumor Cell Detection Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 ANGLE plc Free Circulating Tumor Cell Detection Product Portfolio
- 4.9.5 ANGLE plc Recent Developments
5 Global Free Circulating Tumor Cell Detection Market Scenario by Region
- 5.1 Global Free Circulating Tumor Cell Detection Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Free Circulating Tumor Cell Detection Sales by Region: 2021-2032
- 5.2.1 Global Free Circulating Tumor Cell Detection Sales by Region: 2021-2026
- 5.2.2 Global Free Circulating Tumor Cell Detection Sales by Region: 2027-2032
- 5.3 Global Free Circulating Tumor Cell Detection Revenue by Region: 2021-2032
- 5.3.1 Global Free Circulating Tumor Cell Detection Revenue by Region: 2021-2026
- 5.3.2 Global Free Circulating Tumor Cell Detection Revenue by Region: 2027-2032
- 5.4 North America Free Circulating Tumor Cell Detection Market Facts & Figures by Country
- 5.4.1 North America Free Circulating Tumor Cell Detection Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 5.4.3 North America Free Circulating Tumor Cell Detection Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Free Circulating Tumor Cell Detection Market Facts & Figures by Country
- 5.5.1 Europe Free Circulating Tumor Cell Detection Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 5.5.3 Europe Free Circulating Tumor Cell Detection Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Free Circulating Tumor Cell Detection Market Facts & Figures by Country
- 5.6.1 Asia Pacific Free Circulating Tumor Cell Detection Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Free Circulating Tumor Cell Detection Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Free Circulating Tumor Cell Detection Market Facts & Figures by Country
- 5.7.1 South America Free Circulating Tumor Cell Detection Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 5.7.3 South America Free Circulating Tumor Cell Detection Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Free Circulating Tumor Cell Detection Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Free Circulating Tumor Cell Detection Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Free Circulating Tumor Cell Detection Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Free Circulating Tumor Cell Detection Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Free Circulating Tumor Cell Detection Sales by Type (2021-2032)
- 6.1.1 Global Free Circulating Tumor Cell Detection Sales by Type (2021-2032) & (Units)
- 6.1.2 Global Free Circulating Tumor Cell Detection Sales Market Share by Type (2021-2032)
- 6.2 Global Free Circulating Tumor Cell Detection Revenue by Type (2021-2032)
- 6.2.1 Global Free Circulating Tumor Cell Detection Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Free Circulating Tumor Cell Detection Revenue Market Share by Type (2021-2032)
- 6.3 Global Free Circulating Tumor Cell Detection Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Free Circulating Tumor Cell Detection Sales by Application (2021-2032)
- 7.1.1 Global Free Circulating Tumor Cell Detection Sales by Application (2021-2032) & (Units)
- 7.1.2 Global Free Circulating Tumor Cell Detection Sales Market Share by Application (2021-2032)
- 7.2 Global Free Circulating Tumor Cell Detection Revenue by Application (2021-2032)
- 7.2.1 Global Free Circulating Tumor Cell Detection Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Free Circulating Tumor Cell Detection Revenue Market Share by Application (2021-2032)
- 7.3 Global Free Circulating Tumor Cell Detection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Free Circulating Tumor Cell Detection Value Chain Analysis
- 8.1.1 Free Circulating Tumor Cell Detection Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Free Circulating Tumor Cell Detection Production Mode & Process
- 8.2 Free Circulating Tumor Cell Detection Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Free Circulating Tumor Cell Detection Distributors
- 8.2.3 Free Circulating Tumor Cell Detection Customers
9 Global Free Circulating Tumor Cell Detection Analyzing Market Dynamics
- 9.1 Free Circulating Tumor Cell Detection Industry Trends
- 9.2 Free Circulating Tumor Cell Detection Industry Drivers
- 9.3 Free Circulating Tumor Cell Detection Industry Opportunities and Challenges
- 9.4 Free Circulating Tumor Cell Detection Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst